跳至主要内容
临床试验/NCT06962735
NCT06962735已完成不适用

Effect of Switching From Intermittently Scanned Continuous Glucose Monitoring to Real-time Continuous Glucose Monitoring on Glycemic Outcomes in Adults With Diabetes: A Real-world, Canadian Retrospective Study

LMC Diabetes & Endocrinology Ltd.1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2024年1月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
220
试验地点
1
主要终点
Change in HbA1c at 6-12-month follow-up compared to baseline

研究概览

简要总结

The objective of this retrospective, observational study, is to better understand the real-world glycemic effectiveness of switching to real time continuous glucose monitoring (rtCGM) from intermittently scanned continuous glucose monitoring (isCGM) among adults with type 1 diabetes or type 2 diabetes in Canada.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 years or older as of the index date
  • •Clinical diagnosis of T1D or T2D ≥ one year
  • •Using either MDI or CSII therapy
  • •Initiated a FreeStyle Libre® isCGM device between January 1, 2018 and July 31, 2023 (isCGM cohort)
  • •Switched from a FreeStyle Libre® 1 or Libre 2® isCGM device to a Dexcom® G5 or G6 CGM device between April 1, 2018 and July 31, 2023 (rtCGM cohort)
  • •Baseline HbA1c ≥7.0% for primary objective with rtCGM cohort
  • •Baseline HbA1c ≥8.0% for key secondary objective comparing rtCGM cohort to isCGM cohort
  • •Known rtCGM/isCGM start date (month and year)
  • •Exclusive use of isCGM for ≥ 3 months
  • •≥ one HbA1c value up to 6 months (± 6 weeks) prior to index date (HbA1c value must be after isCGM initiation and no more than 6 weeks after the index date)
  • •≥ one HbA1c value 6-12 months (± 6 weeks) following the index date
  • •Informed consent for their medical record data to be used for research purposes

排除标准

  • •Have a prior history of rtCGM within 12 months of the index date
  • •Are pregnant at the time of isCGM initiation or time of switch to rtCGM
  • •Used the isCGM or rtCGM for < 3 months

结局指标

主要结局

Change in HbA1c at 6-12-month follow-up compared to baseline

时间窗: from index date to 6- to-12-month follow-up

To evaluate change in HbA1c at 6-12-month follow-up compared to baseline after switching from an isCGM system to a rtCGM system in adults with type 1 diabetes

次要结局

  • Change in HbA1c in the rtCGM switch cohort compared to a matched isCGM cohort(from index date to 6- to-12-month follow-up)
  • Change in percent time in target glucose range (TIR) at 6-12 months follow-up(from index date to 6- to-12-month follow-up)
  • Change in percent time below target glucose range (TBR)(from index date to 6- to-12-month follow-up)
  • Change in percent time above target glucose range (TAR)(from index date to 6- to-12-month follow-up)
  • Change in mean glucose(from index date to 6- to-12-month follow-up)
  • Change in standard deviation (SD) of mean glucose(from index date to 6- to-12-month follow-up)
  • Change in coefficient of variation (CV) of mean glucose(from index date to 6- to-12-month follow-up)
  • Change in weight(from index date to 6- to-12-month follow-up)
  • Proportion of patients who achieve HbA1c ≤7.0%(evaluated at 6- to-12-month follow-up)
  • Weekly incidence of self-reported hypoglycemia(evaluated at 6- to-12-month follow-up)
  • Proportion of patients with ≥ 1 self-reported hypoglycemic event(evaluated at 6- to-12-month follow-up)
  • Change in total daily dose (TDD) of insulin(from index date to 6- to-12-month follow-up)
  • Proportion of patients using a Tandem® insulin pump in the rtCGM switch cohort(from index date to 6- to-12-month follow-up)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验